Cancer Diagnosis and Prognosis by Determining Levels of MDM2 and p53 and Antibodies Against MDM2
SK 596
Summary of Invention
The invention provides a method for diagnosing cancer by determining the expression levels or the degrees of gene amplification of p53 and MDM2, whereby an elevated level of either gene or either protein would indicate a cancer diagnosis. Furthermore, the invention provides a method of predicting the progress of cancer, whereby elevated levels of either gene or either protein would indicate a poor prognosis.
Also provided are five monoclonal antibodies against the human MDM2 protein.
Advantages
Monoclonal MDM2 antibodies useful for histochemistry
Areas of Application
Method to aid in the diagnosis and prognosis of several cancers
Lead Inventor
Arnold J. Levine, PhD
Patent Information
- U.S. patent issued: 5,843,684
- PCT application US93/06163: National patent issued in Europe
- National stage applications in Australia, Canada, Japan, Taiwan
Contact Information
Peter Fong, PhD
Tel: 212-639-6181; Fax: 212-717-3439
E-mail: fongp@mskcc.org
Categories
